D. Boral Capital initiated coverage of Pulmonx (LUNG) with a Buy rating and $17 price target The firm says Pulmonx is a commercial-stage medical technology company developing minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease. With increasing physician adoption of the company’s Zephyr Endobronchial Valve, strong reimbursement tailwinds, and international expansion opportunities, Pulmonx is well positioned for “significant growth,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG:
- Pulmonx management to meet virtually with Lake Street
- Pulmonx Corporation’s Earnings Call Reveals Strong Growth and Challenges
- Strong Financial Performance and Strategic Initiatives Drive Pulmonx’s Buy Rating
- Pulmonx Corporation Achieves Record Revenue Growth in 2024
- Closing Bell Movers: Carvana down 8% on earnings, Palantir extends decline